Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.5, pp.1201-5, 2015 (Journal Indexed in SCI Expanded)
Purpose: Benefits of somatostatin analogues have been mostly studied in mixed samples of patients including both functional and non-functional neuroendocrine tumors. This study aimed to examine the response of patients with non-functional metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that received first-line treatment with the somatostatin analogue octreotide LAR.